Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The session is scheduled for September 16 at 8:30 a.m. EDT and will be webcast live, with a replay available on the Events & Presentations page of Helus Pharma's investor relations website. The full press release can be accessed at https://ibn.fm/r0jfC.
The invitation to present at one of the healthcare industry's most prestigious investor conferences underscores Helus Pharma's growing profile in the mental health treatment space. Morgan Stanley's Global Healthcare Conference attracts top institutional investors, analysts, and industry executives, making it a prime venue for companies to showcase their pipelines and strategic vision. For Helus Pharma, this appearance offers a critical opportunity to engage with potential investors and partners at a time when interest in novel psychiatric treatments is intensifying.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company focused on developing proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma seeks to improve the treatment landscape through NSAs that provide durable improvements in mental health.
The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. This designation is reserved for drugs that may offer substantial improvement over existing therapies, and it can expedite development and review. Helus Pharma is also developing HLP004, another proprietary NSA, in Phase 2 for generalized anxiety disorder. Additionally, the company has an extensive research portfolio of investigational NSAs.
Operating in Canada, the United States, the United Kingdom, and Ireland, Helus Pharma is positioning itself as a leader in the emerging field of serotonergic agonists. The company's participation in the Morgan Stanley conference signals its readiness to advance its programs and potentially secure the resources needed to bring these therapies to market. For investors, the fireside chat may provide insights into upcoming milestones, including data readouts and regulatory interactions.
With depression and anxiety affecting millions worldwide and many patients not achieving adequate relief from existing treatments, Helus Pharma's progress could have significant implications for public health. The company's focus on neuroplasticity—the brain's ability to reorganize itself by forming new neural connections—represents a promising avenue for developing more effective and lasting treatments. The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP.
As the conference date approaches, stakeholders will be watching closely to see how Helus Pharma articulates its vision and strategy. The webcast and replay will allow a broader audience to access the discussion, further amplifying the company's message. For more information about Helus Pharma, visit www.helus.com.
